Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,287.60
(
-0.25%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.94
(
-0.50%
)
Bitcoin
76,943.11
(
-0.60%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Thursday, 12/04/2008 1:16:45 PM

Thursday, December 04, 2008 1:16:45 PM

Post# of 257580
MNTA – I’ve confirmed two points regarding the Lovenox ANDA from HSP:

• HSP is seeking to market a generic version of Lovenox vials, but not a generic version of Lovenox syringes.

• Vials comprise only 1% of dollar sales in the US Lovenox market.

No one I have spoken to knows why HSP is not pursuing a generic version of the syringe. (HSP itself won’t comment.) However, that fact that they’re not pursuing it means that HSP’s ANDA can be ignored as round-off error in any economic analysis of the US Lovenox market.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today